−0.070 CAD
−2.75 M CAD
19.58 M CAD
16.37 M
About Crescita Therapeutics, Inc.
Sector
Industry
CEO
Serge Verreault
Website
Headquarters
Laval
Founded
2016
ISIN
CA2258471028
FIGI
BBG008HJRTD5
Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. Its products include Pliaglis, Alyria, Laboratoire Dr Renaud, and Pro-Derm. It operates through the following business segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells non-prescription skincare products. The Licensing and Royalties segment refers to the licensing related to its prescription product. The Manufacturing and Services segment relates to the sale of topical products and product development services. The company was founded on March 1, 2016 and is headquartered in Laval, Canada.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CTX is 0.455 CAD — it hasn't changed in the past 24 hours. Watch Crescita Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange Crescita Therapeutics, Inc. stocks are traded under the ticker CTX.
CTX stock has fallen by −2.15% compared to the previous week, the month change is a −3.19% fall, over the last year Crescita Therapeutics, Inc. has showed a −26.61% decrease.
CTX stock is 0.00% volatile and has beta coefficient of 0.20. Track Crescita Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Crescita Therapeutics, Inc. there?
Today Crescita Therapeutics, Inc. has the market capitalization of 8.86 M, it has increased by 1.10% over the last week.
Yes, you can track Crescita Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CTX net income for the last quarter is 798.00 K CAD, while the quarter before that showed −932.00 K CAD of net income which accounts for 185.62% change. Track more Crescita Therapeutics, Inc. financial stats to get the full picture.
No, CTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Crescita Therapeutics, Inc. EBITDA is −536.00 K CAD, and current EBITDA margin is −9.44%. See more stats in Crescita Therapeutics, Inc. financial statements.
Like other stocks, CTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Crescita Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Crescita Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Crescita Therapeutics, Inc. stock shows the sell signal. See more of Crescita Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.